Clear All
11564 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00069-0353-30 00069-0353 Talazoparib Talzenna 0.25 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Apr 17, 2024 In Use
63539-0295-30 63539-0295 talazoparib Talzenna 1.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec 10, 2018 Jan 31, 2027 In Use
63539-0051-30 63539-0051 Talazoparib Talzenna 0.5 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Jun 21, 2023 Jun 30, 2026 In Use
00069-0296-30 00069-0296 talazoparib Talzenna 0.25 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Oct 26, 2018 Jan 31, 2027 In Use
69656-0103-30 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Jul 1, 2018 Aug 31, 2024 No Longer Used
00310-0679-95 00310-0679 Olaparib Lynparza 150.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug 31, 2017 In Use
00069-0252-30 00069-0252 Talazoparib Talzenna 0.1 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Apr 17, 2024 In Use
00173-0909-13 00173-0909 Niraparib ZEJULA 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Jun 27, 2023 In Use
46014-1195-03 46014-1195 talazoparib Talzenna 1.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Oct 26, 2018 In Use
69656-0103-61 69656-0103 Niraparib Zejula 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Jul 1, 2020 Aug 31, 2024 No Longer Used
69660-0201-91 69660-0201 Rucaparib Rubraca 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec 19, 2016 Dec 31, 2025 In Use
69660-0203-91 69660-0203 Rucaparib Rubraca 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec 19, 2016 Jul 31, 2025 In Use
00003-7125-11 00003-7125 nivolumab and relatlimab-rmbw OPDUALAG 12.0 mg/mL, 4.0 mg/mL Immunotherapy Checkpoint Inhibitor, Monoclonal Antibody PD-1, LAG3 Intravenous Mar 18, 2022 In Use
00006-3026-04 00006-3026 Pembrolizumab Keytruda 25.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Aug 1, 2019 In Use
00003-3734-13 00003-3734 Nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec 8, 2017 In Use
00006-3029-02 00006-3029 Pembrolizumab Keytruda 50.0 mg/2mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Sep 4, 2014 Dec 21, 2015 In Use
00006-3026-02 00006-3026 Pembrolizumab Keytruda 25.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Jan 15, 2015 In Use
00003-3756-14 00003-3756 nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Aug 30, 2021 In Use
83654-0105-01 83654-0105 Penpulimab Penpulimab 100.0 mg/10mL Immunotherapy Monoclonal Antibody PD-1 Intravenous Apr 23, 2025 In Use
00003-6120-01 00003-6120 Nivolumab and hyaluronidase-nvhy OPDIVO QVANTIG 2000.0 U/mL, 120.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Subcutaneous Jan 2, 2025 In Use
50881-0006-03 50881-0006 Retifanlimab-dlwr ZYNYZ 25.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Mar 22, 2023 In Use
00003-3774-12 00003-3774 Nivolumab Opdivo 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec 22, 2014 In Use
70114-0340-01 70114-0340 Toripalimab-tpzi LOQTORZI 240.0 mg/6mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Oct 27, 2023 In Use
00003-3772-11 00003-3772 Nivolumab Opdivo 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec 22, 2014 In Use
72579-0121-01 72579-0121 Tislelizumab, Tislelizumab-jsgr TEVIMBRA 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Mar 14, 2024 In Use

Found 11564 results — Export these results